CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis & Neurotoxicity Research

Executive Summary: CA-074 is a potent, selective cathepsin B inhibitor (Ki = 2–5 nM), enabling targeted investigation of cathepsin B–mediated processes in cancer, neurodegeneration, and immunity (product page). It demonstrates >1000-fold selectivity over cathepsins H and L, making it valuable for mechanistic studies of proteolytic cascades (Liu et al., 2023). CA-074 reduces bone metastasis in breast cancer mouse models and suppresses Abeta42-induced neurotoxicity in vitro. The compound is highly soluble, exhibits negligible cytotoxicity at 10 mM in cell culture, and is effective in vivo at 50 mg/kg via intraperitoneal injection. Its use has clarified the role of cathepsin B in lysosomal membrane permeabilization and necroptosis, as well as in immune modulation (related analysis).

Biological Rationale

Cathepsin B is a lysosomal cysteine protease abundantly expressed in many mammalian tissues. It plays a central role in intracellular protein degradation, extracellular matrix remodeling, and regulated cell death. Dysregulation of cathepsin B activity has been implicated in cancer metastasis, particularly in promoting tumor cell invasion and bone metastasis, as well as in neurotoxicity and inflammatory responses (Liu et al., 2023). Cathepsin B activity is also critical in lysosomal membrane permeabilization (LMP), a process leading to the release of lysosomal enzymes and subsequent cell death. Selective inhibition of cathepsin B is essential for distinguishing its unique contributions from those of other lysosomal cathepsins such as H and L. CA-074, as a small-molecule inhibitor, enables precise modulation of cathepsin B activity, empowering studies on metastatic progression, regulated necrosis (necroptosis), and immune cell function (contrast: highlights CA-074's unique nanomolar selectivity for mechanistic dissection).

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a synthetic small molecule with the chemical name (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid (molecular weight: 383.44 g/mol) (product page). It binds to the active site of cathepsin B, irreversibly inhibiting its cysteine protease activity. The inhibition constant (Ki) for cathepsin B is 2–5 nM, while for cathepsins H and L, Ki values are 40–200 µM, confirming high selectivity. By blocking cathepsin B, CA-074 prevents the proteolytic cleavage of substrates involved in extracellular matrix degradation, tumor cell invasion, and death signaling cascades. In the context of necroptosis, CA-074 inhibits cathepsin B–mediated proteolysis released upon lysosomal membrane permeabilization, thereby protecting cells from MLKL-induced necrotic death (Liu et al., 2023). In immune cells, CA-074 modulates the Th-2/Th-1 balance, reducing IgE and IgG1 antibody production and shifting cytokine responses toward Th-1 dominance.

Evidence & Benchmarks

• CA-074 binds cathepsin B with a Ki of 2–5 nM, demonstrating >1000-fold selectivity over cathepsins H and L (Ki = 40–200 µM) (ApexBio product documentation).
• In 4T1.2 breast cancer mouse models, CA-074 administered intraperitoneally at 50 mg/kg reduced bone metastasis without affecting primary tumor volume (Liu et al., 2023).
• CA-074 suppresses neurotoxicity in vitro, reducing cell death induced by Abeta42-activated microglial cells (review of neurotoxicity evidence).
• In cell culture, CA-074 exhibits negligible cytotoxicity up to 10 mM concentration in standard conditions (37°C, 5% CO₂) (ApexBio).
• Upon MLKL-induced necroptosis, inhibition or knockdown of cathepsin B by CA-074 protects cells from LMP-mediated death (Liu et al., 2023).
• CA-074 shifts immune response from Th-2 to Th-1, reducing IgE and IgG1 antibody production in murine models (internal review).

Applications, Limits & Misconceptions

CA-074 is optimized for research on:

• Cancer metastasis: Probing cathepsin B’s role in tumor cell invasion and bone metastasis (extends: this piece connects MLKL-necroptosis to metastasis pathways).
• Neurotoxicity: Dissecting cathepsin B–dependent neurodegenerative mechanisms.
• Regulated cell death: Specifically, necroptosis and lysosomal membrane permeabilization, as CA-074 blocks LMP-mediated cell death (Liu et al., 2023).
• Immune modulation: Shifting T helper cell activity and antibody production profiles.

Common Pitfalls or Misconceptions

• CA-074 does not inhibit cathepsin H or L at nanomolar concentrations; high micromolar doses are required for off-target effects.
• It is not a general lysosomal protease inhibitor; specificity is for cathepsin B.
• CA-074’s effects on necroptosis are contingent on cathepsin B–mediated LMP; it does not block upstream MLKL activation.
• In vivo efficacy is demonstrated in mice at 50 mg/kg i.p.; other administration routes or species may require optimization.
• Long-term storage of CA-074 solutions is not recommended; use fresh solutions for reproducibility.

Workflow Integration & Parameters

CA-074 is supplied as a lyophilized powder for reconstitution. It is soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL with ultrasonic assistance). For in vitro studies, stock solutions (10–20 mM) are prepared in DMSO and diluted into culture medium to final concentrations typically ranging from 1–100 µM. CA-074 is stable at -20°C; avoid repeated freeze-thaw cycles. For in vivo work, intraperitoneal injection at 50 mg/kg has demonstrated efficacy in reducing bone metastasis in murine models. Solutions should be freshly prepared and used within one week. In cell-based assays, verify cytotoxicity at chosen concentrations; CA-074 is non-toxic at ≤10 mM. Proper negative and positive controls (e.g., vehicle, non-selective cysteine protease inhibitors) are critical for robust data interpretation (A1926 kit).

Conclusion & Outlook

CA-074, as a selective cathepsin B inhibitor, is a validated tool for dissecting critical proteolytic and immune pathways in cancer, neurodegeneration, and cell death research. Its nanomolar potency and high selectivity enable the attribution of observed phenotypes specifically to cathepsin B activity. Recent studies have established its pivotal role in blocking MLKL-mediated necroptosis via lysosomal membrane permeabilization (Liu et al., 2023). Future research may clarify additional roles in immune modulation and metastatic disease. For comprehensive mechanistic and translational studies, CA-074 remains the gold-standard tool compound in the field. For in-depth workflows and advanced protocol guidance, see the CA-074, Cathepsin B inhibitor product page.